CTX-110 is a gene-modified cell therapy commercialized by CRISPR Therapeutics, with a leading Phase I program in B-Cell Non-Hodgkin Lymphoma. According to Globaldata, it is involved in 3 clinical trials, of which 2 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of CTX-110’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for CTX-110 is expected to reach an annual total of $377 mn by 2036 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

CTX-110 Overview

CTX-110 (previously known as CTX-101) is under development for the treatment of B-cell acute lymphocytic leukemia and B-cell non-hodgkin lymphomas including DLBCL, transformed follicular lymphoma, Richter’s transformation of CLL and acute lymphoblastic leukemia. The drug candidate consists of genetically modified chimeric antigen receptor (CAR-T) cells that target tumor cells expressing B lymphocyte antigen CD19. It is administered by intravenous route. It is developed based on CRISPR’s gene-editing technology.

CRISPR Therapeutics Overview

CRISPR Therapeutics (CRISPR) is a gene editing company. It focuses on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a gene-editing technology that modifies, deletes or corrects disease-causing abnormalities at its genetic sources. Its major development programs include ex vivo programs involving gene editing of hematopoietic cells; ex vivo programs in immuno-oncology; in vivo programs targeting the liver and additional in vivo programs targeting other organ systems including muscle and lung. It has research and development operations in Cambridge, Massachusetts, the US and business operations in London, the UK. CRISPR is headquartered in Zug, Switzerland.

The company reported revenues of (US Dollars) US$915 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$0.7 million in FY2020. The operating profit of the company was US$373.5 million in FY2021, compared to an operating loss of US$354.4 million in FY2020. The net profit of the company was US$377.7 million in FY2021, compared to a net loss of US$348.9 million in FY2020. The company reported revenues of US$0.1 million for the third quarter ended September 2022, a decrease of 40.5% over the previous quarter.

For a complete picture of CTX-110’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.